Ventilator

Vapotherm to Participate in the William Blair 41st Annual Growth Stock Conference

Retrieved on: 
Tuesday, May 25, 2021
Health, Medical Supplies, Other Health, Medical devices, Medical specialties, Medicine, Clinical medicine, Respiratory therapy, Medical emergencies, Respiratory diseases, Ventilator, Hypercapnia, Vapotherm, Respiratory therapist

Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021 via webcast.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021 via webcast.
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Over 2.8 million patients have been treated with the use of Vapotherm high velocity therapy systems.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.

30,000 Ventilators and 13,000 Monitors Land in India - American India Foundation and Xerox Come Together for COVID 19 Relief

Retrieved on: 
Wednesday, May 19, 2021
Philanthropy, Medical Supplies, Health, Medical devices, Infectious diseases, Foundation, General Health, Medicine, Respiratory therapy, Industrial gases, Oxygen, Clinical medicine, Health sciences, Ventilator, Oxygen concentrator, Oxygen therapy

b'The American India Foundation (AIF) has shipped more than 30,000 single use, self-powered ventilators and 13,000 monitors to India, an in-kind donation received from Xerox, in an immediate response to the government\xe2\x80\x99s appeal for NGOs to aid \xe2\x80\x98COVID-19 interventions in India, during this \xe2\x80\x98once in a century crisis.\xe2\x80\x99\nThis press release features multimedia.

Key Points: 
  • b'The American India Foundation (AIF) has shipped more than 30,000 single use, self-powered ventilators and 13,000 monitors to India, an in-kind donation received from Xerox, in an immediate response to the government\xe2\x80\x99s appeal for NGOs to aid \xe2\x80\x98COVID-19 interventions in India, during this \xe2\x80\x98once in a century crisis.\xe2\x80\x99\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210519005606/en/\nShipped by FedEx in collaboration with MetLife Foundation, the ventilators are disposable, hands-free devices that do not require power from electricity or batteries, making them versatile and appropriate, especially for usage in Tier III cities and rural areas that may not have a steady power supply.
  • The hands-free ventilators offer a secure airway using a continuous gas source.
  • Leveraging its 20 years of experience working in humanitarian crisis, with various state governments and civil society organisations, AIF has so far, ordered 5,500 oxygen concentrators, 2,400 hospital beds and Oxygen Plants across 25 cities of the country.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210519005606/en/\n'

CorVent Medical Secures CE Mark Approval For Its Critical Care RESPOND-19™ Ventilator

Retrieved on: 
Tuesday, May 18, 2021
Respiratory therapy, Ventilator, Health care, Emergency Use Authorization, Food and Drug Administration, Health, Medicine

b'SANTA CLARA, Calif., May 18, 2021 /PRNewswire/ -- CorVent Medical , a private medtech company focused on developing versatile, lifesaving ventilators for critical care, announced that it has received CE Mark approval and is ready to launch commercial use of its RESPOND-19 Ventilator in Europe.

Key Points: 
  • b'SANTA CLARA, Calif., May 18, 2021 /PRNewswire/ -- CorVent Medical , a private medtech company focused on developing versatile, lifesaving ventilators for critical care, announced that it has received CE Mark approval and is ready to launch commercial use of its RESPOND-19 Ventilator in Europe.
  • Felix Herth, pulmonologist and Medical Director at Thoraxklinik-Heidelberg University Hospital in Germany.
  • "The system\'s advanced antiviral protection makes the RESPOND-19 Ventilator an invaluable resource for limiting viral spread, protecting physicians and staff.
  • The RESPOND-19 Ventilator recently received FDA Emergency Use Authorization (EUA), is CE Marked and available for sale in countries that accept those regulatory approvals.

CorVent Medical Secures CE Mark Approval For Its Critical Care RESPOND-19™ Ventilator

Retrieved on: 
Tuesday, May 18, 2021
Respiratory therapy, Ventilator, Health care, Emergency Use Authorization, Food and Drug Administration, Health, Medicine

b'SANTA CLARA, Calif., May 18, 2021 /PRNewswire/ -- CorVent Medical , a private medtech company focused on developing versatile, lifesaving ventilators for critical care, announced that it has received CE Mark approval and is ready to launch commercial use of its RESPOND-19 Ventilator in Europe.

Key Points: 
  • b'SANTA CLARA, Calif., May 18, 2021 /PRNewswire/ -- CorVent Medical , a private medtech company focused on developing versatile, lifesaving ventilators for critical care, announced that it has received CE Mark approval and is ready to launch commercial use of its RESPOND-19 Ventilator in Europe.
  • Felix Herth, pulmonologist and Medical Director at Thoraxklinik-Heidelberg University Hospital in Germany.
  • "The system\'s advanced antiviral protection makes the RESPOND-19 Ventilator an invaluable resource for limiting viral spread, protecting physicians and staff.
  • The RESPOND-19 Ventilator recently received FDA Emergency Use Authorization (EUA), is CE Marked and available for sale in countries that accept those regulatory approvals.

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

Retrieved on: 
Tuesday, May 18, 2021
Respiratory diseases, Medical specialties, Clinical medicine, Respiratory therapy, Infectious diseases, Pneumonia, Ventilator-associated pneumonia, Bronchiectasis, Ventilator, Sputum, Respiratory tract infection, COVID-19

The ABT measures bacterial load in suspected respiratory infections and may represent an effective alternative to sputum culture-based diagnostics.

Key Points: 
  • The ABT measures bacterial load in suspected respiratory infections and may represent an effective alternative to sputum culture-based diagnostics.
  • Approximately 25% of the 1.7 million intensive care unit (ICU) patients who are on ventilators each year develop VAP.
  • The non-radioactive, isotopic ratio of 13CO2/12CO2 in the exhaled breath of the patient is measured by the Avisa spectrometer.
  • Avisa is planning pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials next year.

CytoDyn Signs Distribution Agreement with Macleods Pharmaceuticals Ltd. to Pursue EUA and Compassionate Use Access to Leronlimab in India

Retrieved on: 
Thursday, May 13, 2021
Leronlimab, Respiratory therapy, Ventilator, Health care, Medicine, Health

This commercial agreement will enable Macleods to sell leronlimab in India following regulatory clearance.\nNader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, stated, \xe2\x80\x9cWe are delighted Macleods Pharmaceuticals reached out to CytoDyn and equally excited to reach this agreement with their team so quickly.

Key Points: 
  • This commercial agreement will enable Macleods to sell leronlimab in India following regulatory clearance.\nNader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, stated, \xe2\x80\x9cWe are delighted Macleods Pharmaceuticals reached out to CytoDyn and equally excited to reach this agreement with their team so quickly.
  • From the time they first contacted us about our drug, we were able to conclude this agreement within a few days.
  • It is an honor to work with an organization so motivated to bring leronlimab to COVID-19 patients in India.
  • We believe there is an immediate need for leronlimab in our country, to save COVID-19 infected patients who are on ventilators.

Artificial Intelligence Tool Uses Chest X-ray to Differentiate Worst Cases of COVID-19

Retrieved on: 
Wednesday, May 12, 2021
New York University, Respiratory therapy, Midtown Manhattan, NYU Langone Health, Langone, Ventilator, Health care

For reasons not yet fully understood, the health of some COVID-19 patients suddenly worsens, requiring intensive care, and increasing their chances of dying.\nIn a bid to address this need, the NYU Langone team fed not only X-ray information into their computer analysis, but also patients\' age, race, and gender, along with several vital signs and laboratory test results, including weight, body temperature, and blood immune cell levels.

Key Points: 
  • For reasons not yet fully understood, the health of some COVID-19 patients suddenly worsens, requiring intensive care, and increasing their chances of dying.\nIn a bid to address this need, the NYU Langone team fed not only X-ray information into their computer analysis, but also patients\' age, race, and gender, along with several vital signs and laboratory test results, including weight, body temperature, and blood immune cell levels.
  • Also factored into their mathematical models, which can learn from examples, were the need for a mechanical ventilator and whether each patient went on to survive (2,405) or die (538) from their infections.\nResearchers then tested the predictive value of the software tool on 770 chest X-rays from 718 other patients admitted for COVID-19 through the emergency room at NYU Langone hospitals from March 3 to June 28, 2020.
  • He says the team plans to add more patient information as it becomes available.
  • He also says the team is evaluating what additional clinical test results could be used to improve their test model.\nGeras says he hopes, as part of further research, to soon deploy the NYU COVID-19 classification test to emergency physicians and radiologists.

Caterpillar and the Caterpillar Foundation Donate Additional $3.4 Million in COVID-19 Relief

Retrieved on: 
Thursday, May 6, 2021
Caterpillar Inc., Ventilator, Sustainability, Companies, Articles, Manufacturing

In addition to the Foundation\'s efforts, Caterpillar India is providing an initial contribution of $1.4 million, enabling an additional supply of oxygen, donating beds with ventilator support to hospitals, supporting vaccination drives and setting up temporary relief shelters.

Key Points: 
  • In addition to the Foundation\'s efforts, Caterpillar India is providing an initial contribution of $1.4 million, enabling an additional supply of oxygen, donating beds with ventilator support to hospitals, supporting vaccination drives and setting up temporary relief shelters.
  • Since 1925, we\'ve been driving sustainable progress and helping customers build a better world through innovative products and services.
  • These products and services, backed by our global dealer network, provide exceptional value to help our customers succeed.
  • To learn more about the global impact of the Caterpillar Foundation, visit caterpillar.com/foundation.

Global Task Force on Pandemic Response Launched by Leading Companies and Business Associations to Address Urgent COVID-19 Surges

Retrieved on: 
Wednesday, May 5, 2021
Infectious diseases, Health, Other Health, Medical technology, Health care, Respiratory therapy, Equipment, Medical equipment, Ventilator, Oxygen concentrator, Medtronic, FedEx, the U.S. Chamber of Commerce, Business Roundtable, THE U.S. CHAMBER OF COMMERCE, BUSINESS ROUNDTABLE

The first ventilators procured by the U.S. Chamber of Commerce Foundation will arrive in India today, with all remaining ventilators expected to arrive by June 3.

Key Points: 
  • The first ventilators procured by the U.S. Chamber of Commerce Foundation will arrive in India today, with all remaining ventilators expected to arrive by June 3.
  • Medtronic will manufacture the ventilators and handle end-to-end shipping, installation and ongoing and virtual training .
  • ( Fact Sheet )\nDelivering 25,000 oxygen concentrators to India by the end of May, with transportation support from FedEx.
  • Their companies\xe2\x80\x99 total value, over $20 trillion, accounts for approximately half of the value of all publicly-traded companies in the United States.

COVID-19 Horror in India From a Doctor's Perspective

Retrieved on: 
Wednesday, May 5, 2021
Medicine, Health, Clinical medicine, Respiratory therapy, Diving medicine, Oxygen, Ventilator, Oxygen therapy, COVID-19 pandemic, Saudi Arabia, Draft:Oxygen Crisis in India

They have nothing to offer the sick, neither oxygen nor hospital beds, breathing treatments or any medical relief.

Key Points: 
  • They have nothing to offer the sick, neither oxygen nor hospital beds, breathing treatments or any medical relief.
  • "\n"According to news reports at least 30,000 people are dying each day, however the real numbers are likely much higher," says Dr.
  • "\n"The situation in India now represents the worst crisis any country has seen since the beginning of the COVID-19 pandemic.
  • The US, Russia, China, Saudi Arabia, several European and neighboring countries including Pakistan have committed to supply oxygen, ventilators, medical supplies and equipment to India.